Amoxicillin

Description

Formulations of amoxicillin capsules, USP contain amoxicillin, a semi-synthetic antibiotic and an analog of ampicillin, exhibiting a broad spectrum of bactericidal activity against various gram-positive and gram-negative microorganisms. The chemical structure of amoxicillin is defined as (2S, 5R, 6R)-6-((R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo 3.2.0 heptane-2-carboxylic acid trihydrate. The molecular formula is C16H19N3O5S∙3H2O, with a molecular weight of 419.45.

Amoxicillin capsules are intended for oral administration, available in two strengths: 250 mg and 500 mg of amoxicillin. The 250 mg capsules feature a caramel opaque cap and buff opaque body, imprinted with "AA" and "820," respectively. Inactive ingredients in the 250 mg formulation include magnesium stearate, sodium lauryl sulfate, D&C Yellow No. 10, FD&C Yellow No. 6, FD&C Blue No. 1, FD&C Red No. 3, titanium dioxide, and gelatin. The 500 mg capsules have a buff opaque cap and buff opaque body, imprinted with "AA" and "825." The inactive ingredients for the 500 mg formulation consist of magnesium stearate, sodium lauryl sulfate, D&C Yellow No. 10, FD&C Yellow No. 6, titanium dioxide, and gelatin.

Uses and Indications

Amoxicillin is indicated for the treatment of infections caused by susceptible (only β-lactamase-negative) strains of designated microorganisms in the following conditions:

Infections of the Ear, Nose, and Throat Amoxicillin is indicated for infections due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Infections of the Genitourinary Tract This drug is indicated for infections caused by E. coli, P. mirabilis, or E. faecalis.

Infections of the Skin and Skin Structure Amoxicillin is indicated for infections due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli.

Infections of the Lower Respiratory Tract This drug is indicated for infections caused by Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Gonorrhea Amoxicillin is indicated for the treatment of acute uncomplicated ano-genital and urethral infections due to N. gonorrhoeae in both males and females.

H. pylori Eradication Amoxicillin is indicated to reduce the risk of duodenal ulcer recurrence as part of a treatment regimen for H. pylori infection.

Triple Therapy In combination with clarithromycin and lansoprazole, amoxicillin is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or with a 1-year history of a duodenal ulcer) to eradicate H. pylori.

Dual Therapy Amoxicillin, in combination with lansoprazole delayed-release capsules, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or with a 1-year history of a duodenal ulcer) who are allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.

No teratogenic or nonteratogenic effects have been mentioned.

Dosage and Administration

Amoxicillin capsules may be administered without regard to meals.

For neonates and infants aged ≤ 12 weeks (≤ 3 months), the recommended upper dose is 30 mg/kg/day, divided every 12 hours.

In adults and pediatric patients over 3 months, dosing varies by infection type:

Ear/Nose/Throat Infections:

• For mild to moderate infections:

  • Usual adult dose: 500 mg every 12 hours or 250 mg every 8 hours.

  • Usual dose for children: 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours.

• For severe infections:

  • Usual adult dose: 875 mg every 12 hours or 500 mg every 8 hours.

  • Usual dose for children: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours.

Lower Respiratory Tract Infections:

• For both mild/moderate and severe infections:

  • Usual adult dose: 875 mg every 12 hours or 500 mg every 8 hours.

  • Usual dose for children: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours.

Skin/Skin Structure Infections:

• For mild to moderate infections:

  • Usual adult dose: 500 mg every 12 hours or 250 mg every 8 hours.

  • Usual dose for children: 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours.

• For severe infections:

  • Usual adult dose: 875 mg every 12 hours or 500 mg every 8 hours.

  • Usual dose for children: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours.

Genitourinary Tract Infections:

• For mild to moderate infections:

  • Usual adult dose: 500 mg every 12 hours or 250 mg every 8 hours.

  • Usual dose for children: 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours.

• For severe infections:

  • Usual adult dose: 875 mg every 12 hours or 500 mg every 8 hours.

  • Usual dose for children: 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours.

Gonorrhea (Acute, Uncomplicated Ano-genital and Urethral Infections):

• Usual adult dose: 3 grams as a single oral dose.

• Usual dose for prepubertal children: 50 mg/kg Amoxicillin, combined with 25 mg/kg probenecid as a single dose (Note: Probenecid is contraindicated in children under 2 years; this regimen should not be used in these cases).

General recommendations include continuing treatment for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication is obtained. For infections caused by Streptococcus pyogenes, a minimum of 10 days of treatment is recommended to prevent the occurrence of acute rheumatic fever.

For adults with impaired renal function, dosing adjustments are necessary:

• Patients with a glomerular filtration rate (GFR) of < 30 mL/min should not receive the 875 mg tablet.

• Patients with a GFR of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection.

• Patients with a GFR of < 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on the severity of the infection.

• Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, with an additional dose both during and at the end of dialysis, depending on the severity of the infection.

Contraindications

A history of allergic reaction to any penicillins is a contraindication for use. Additionally, ampicillin-class antibiotics should not be administered to patients with mononucleosis due to the potential for severe adverse reactions.

Warnings and Precautions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients undergoing penicillin therapy. Although anaphylaxis is more frequently associated with parenteral administration, it has also occurred in patients receiving oral penicillins. Individuals with a history of penicillin hypersensitivity and/or sensitivity to multiple allergens are at a higher risk for these reactions. Notably, there have been instances of severe reactions in patients with a history of penicillin hypersensitivity who were treated with cephalosporins. Prior to initiating therapy with amoxicillin, a thorough inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens is essential. Should an allergic reaction occur, amoxicillin must be discontinued immediately, and appropriate therapeutic measures should be instituted.

In the event of serious anaphylactic reactions, immediate emergency treatment with epinephrine is required. Additional interventions may include the administration of oxygen, intravenous steroids, and airway management, including intubation, as clinically indicated.

Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including amoxicillin, and can range from mild diarrhea to fatal colitis. The use of antibacterial agents disrupts the normal flora of the colon, leading to an overgrowth of C. difficile, which produces toxins A and B that contribute to CDAD. Hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality, as these infections may be refractory to antimicrobial therapy and could necessitate colectomy. CDAD should be considered in all patients presenting with diarrhea following antibiotic use, and careful medical history is warranted, as CDAD can occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Management should include appropriate fluid and electrolyte replacement, protein supplementation, antibiotic treatment for C. difficile, and surgical evaluation as clinically indicated.

Healthcare professionals should remain vigilant for the possibility of superinfections with mycotic or bacterial pathogens during therapy. If superinfections occur, amoxicillin should be discontinued, and appropriate therapy should be initiated. Additionally, a significant percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash; therefore, ampicillin-class antibiotics should not be administered to patients with mononucleosis. Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to benefit the patient and may increase the risk of developing drug-resistant bacteria.

Periodic assessment of renal, hepatic, and hematopoietic function should be conducted during prolonged therapy with amoxicillin, as with any potent drug. Furthermore, all patients diagnosed with gonorrhea should undergo a serologic test for syphilis at the time of diagnosis, and those treated with amoxicillin should have a follow-up serologic test for syphilis after three months.

In summary, if an allergic reaction occurs, amoxicillin should be discontinued immediately, and appropriate therapy should be instituted.

Side Effects

Patients receiving treatment may experience a range of adverse reactions, which can be categorized by seriousness and frequency.

Serious adverse reactions include anaphylaxis, which has been reported in patients undergoing penicillin therapy. These reactions can be serious and occasionally fatal, particularly in individuals with a history of penicillin hypersensitivity or sensitivity to multiple allergens. Immediate emergency treatment with epinephrine is required for serious anaphylactic reactions, along with oxygen, intravenous steroids, and airway management as necessary. Additionally, Clostridium difficile associated diarrhea (CDAD) has been observed with nearly all antibacterial agents, including amoxicillin, and can vary in severity from mild diarrhea to fatal colitis. Symptoms of CDAD may occur up to two months after antibiotic administration, necessitating careful medical history evaluation in patients presenting with diarrhea following treatment.

Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and black hairy tongue. Hemorrhagic or pseudomembranous colitis may also occur, with symptoms potentially arising during or after antibiotic treatment.

Hypersensitivity reactions are notable and can include a variety of manifestations such as serum sickness-like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria. These reactions may be managed with antihistamines and, if necessary, systemic corticosteroids. Amoxicillin should be discontinued unless the treating physician deems the condition being treated life-threatening and only amenable to amoxicillin therapy.

Liver-related adverse reactions have been noted, including moderate rises in AST (SGOT) and/or ALT (SGPT), the significance of which remains unknown. Reports of hepatic dysfunction, such as cholestatic jaundice, hepatic cholestasis, and acute cytolytic hepatitis, have also been documented.

Renal adverse reactions include crystalluria. Hemic and lymphatic system reactions may manifest as anemia (including hemolytic anemia), thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis. These hematological reactions are generally reversible upon discontinuation of therapy and are believed to be hypersensitivity phenomena.

Central nervous system effects, although reported rarely, can include reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and dizziness.

Miscellaneous adverse reactions include tooth discoloration (brown, yellow, or gray staining), which has been reported rarely, primarily in pediatric patients. In most cases, discoloration was reduced or eliminated with brushing or dental cleaning.

Drug Interactions

Concurrent administration of probenecid with amoxicillin may lead to decreased renal tubular secretion of amoxicillin, resulting in increased and prolonged blood levels of the antibiotic. Monitoring of amoxicillin levels may be warranted in patients receiving this combination.

Antibiotics such as chloramphenicol, macrolides, sulfonamides, and tetracyclines have the potential to interfere with the bactericidal activity of penicillin, including amoxicillin. While this interaction has been demonstrated in vitro, its clinical significance remains inadequately documented. Caution is advised when these agents are used concurrently.

Amoxicillin, like other antibiotics, may disrupt gut flora, which can lead to decreased reabsorption of estrogen and reduced efficacy of combined oral estrogen/progesterone contraceptives. Patients using hormonal contraceptives should be advised to consider alternative or additional contraceptive methods during and after treatment with amoxicillin.

High concentrations of ampicillin in urine may cause false-positive results in glucose testing when using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. It is recommended to utilize glucose tests based on enzymatic glucose oxidase reactions, such as CLINISTIX®, to avoid this issue. This potential for false-positive results may also apply to amoxicillin.

In pregnant women administered ampicillin, a transient decrease in plasma concentrations of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been observed. This effect may similarly occur with amoxicillin, warranting careful monitoring of hormone levels in pregnant patients receiving this treatment.

Packaging & NDC

The table below lists all NDC Code configurations of Amoxicillin, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients, particularly neonates and young infants, may experience delayed elimination of amoxicillin due to incompletely developed renal function. Therefore, dosing of amoxicillin should be modified for pediatric patients aged 12 weeks or younger (≤ 3 months) to ensure safety and efficacy.

Geriatric Use

An analysis of clinical studies involving amoxicillin included subjects aged 65 and over to assess any differences in response compared to younger individuals. Among the 1,811 subjects treated with amoxicillin capsules, 85% were under 60 years of age, while 15% were aged 61 years and older, with 7% being 71 years or older. The findings from this analysis, along with other clinical experiences, have not indicated significant differences in responses between elderly patients and their younger counterparts. However, it is important to note that a greater sensitivity to the drug in some older individuals cannot be excluded.

Amoxicillin is primarily excreted by the kidneys, which raises concerns regarding the potential for toxic reactions, particularly in patients with impaired renal function. Given that geriatric patients are more likely to experience decreased renal function, careful consideration should be given to dose selection in this population. It may be beneficial to monitor renal function in elderly patients to mitigate the risk of adverse effects associated with renal impairment.

Pregnancy

Pregnancy Category B indicates that reproduction studies conducted in mice and rats at doses up to 10 times the human dose have shown no evidence of impaired fertility or harm to the fetus due to amoxicillin. However, there are no adequate and well-controlled studies in pregnant women.

Due to the limitations of animal reproduction studies in predicting human response, amoxicillin should be used during pregnancy only if clearly needed. Healthcare professionals are advised to weigh the potential benefits against any possible risks when considering the use of this medication in pregnant patients.

Lactation

Penicillins, including amoxicillin, have been shown to be excreted in human milk. The use of amoxicillin by nursing mothers may lead to sensitization of breastfed infants. Therefore, caution should be exercised when administering amoxicillin to lactating mothers.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, it is imperative to discontinue the medication immediately and provide symptomatic treatment along with supportive measures as necessary. If the overdosage has occurred very recently and there are no contraindications, an attempt to induce emesis or utilize other methods for the removal of the drug from the stomach may be considered.

A prospective study involving 51 pediatric patients at a poison-control center indicated that overdosages of amoxicillin less than 250 mg/kg are generally not associated with significant clinical symptoms and do not necessitate gastric emptying. However, it is important to monitor for potential complications.

Reports have documented cases of interstitial nephritis leading to oliguric renal failure following amoxicillin overdosage in a small number of patients. Additionally, crystalluria has been observed, which in some instances has resulted in renal failure in both adult and pediatric populations. To mitigate the risk of crystalluria, it is essential to maintain adequate fluid intake and promote diuresis.

Renal impairment resulting from overdosage appears to be reversible upon cessation of amoxicillin administration. It is noteworthy that patients with impaired renal function may experience higher blood levels of the drug due to decreased renal clearance. In cases of severe overdosage, hemodialysis may be employed to facilitate the removal of amoxicillin from circulation.

Nonclinical Toxicology

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of the compound. While specific studies to detect the mutagenic potential of amoxicillin alone have not been conducted, data from tests on a 4:1 mixture of amoxicillin and potassium clavulanate provide relevant insights.

The combination of amoxicillin and potassium clavulanate was found to be non-mutagenic in both the Ames bacterial mutation assay and the yeast gene conversion assay. However, it exhibited weakly positive results in the mouse lymphoma assay, where the observed trend toward increased mutation frequencies occurred at doses that were also associated with decreased cell survival. Additionally, this combination was negative in the mouse micronucleus test and in the dominant lethal assay in mice.

Potassium clavulanate alone was tested in the Ames bacterial mutation assay and the mouse micronucleus test, yielding negative results in both assays.

In a multi-generation reproduction study conducted in rats, no impairment of fertility or other adverse reproductive effects were observed at doses up to 500 mg/kg, which is approximately three times the human dose when adjusted for body surface area.

Postmarketing Experience

Postmarketing experience has identified several adverse events associated with the use of antibacterial agents, including amoxicillin. Clostridium difficile associated diarrhea (CDAD) has been reported, which can range in severity from mild diarrhea to fatal colitis. The alteration of normal colonic flora due to antibacterial treatment can lead to an overgrowth of C. difficile, which produces toxins A and B contributing to CDAD. Hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality, and infections may be refractory to antimicrobial therapy, potentially necessitating colectomy. CDAD should be considered in all patients presenting with diarrhea following antibiotic use, and careful medical history is essential, as cases have been reported to occur over two months post-administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued, and appropriate management should be initiated.

Additional adverse reactions reported with the use of penicillins include:

• Infections and Infestations: Mucocutaneous candidiasis.

• Gastrointestinal: Nausea, vomiting, diarrhea, black hairy tongue, and hemorrhagic/pseudomembranous colitis, with the onset of pseudomembranous colitis symptoms potentially occurring during or after treatment.

• Hypersensitivity Reactions: Anaphylaxis, serum sickness-like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria. These reactions may be managed with antihistamines and systemic corticosteroids if necessary. Amoxicillin should be discontinued unless the treating physician deems the condition life-threatening and only amenable to amoxicillin therapy.

• Liver: Moderate rises in AST (SGOT) and/or ALT (SGPT) have been noted, though the significance remains unclear. Reports of hepatic dysfunction, including cholestatic jaundice, hepatic cholestasis, and acute cytolytic hepatitis, have also been documented.

• Renal: Crystalluria has been reported.

• Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis, have been observed during therapy. These reactions are typically reversible upon discontinuation and are believed to be hypersensitivity phenomena.

• Central Nervous System: Rare reports of reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been noted.

• Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been rarely reported, primarily in pediatric patients, with most cases showing improvement or resolution with dental cleaning or brushing.

Patient Counseling

Healthcare providers should advise patients that amoxicillin may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed. It is important to counsel patients that antibacterial drugs, including amoxicillin, are effective only for treating bacterial infections and do not have any effect on viral infections, such as the common cold.

When prescribing amoxicillin for a bacterial infection, healthcare providers should emphasize the importance of adhering to the prescribed regimen. Patients should be informed that while it is common to feel better early in the course of therapy, it is crucial to take the medication exactly as directed. Skipping doses or failing to complete the full course of therapy may reduce the effectiveness of the treatment and increase the risk of bacteria developing resistance, which could render amoxicillin or other antibacterial drugs ineffective in the future.

Additionally, healthcare providers should make patients aware that diarrhea is a common side effect associated with antibiotic use, typically resolving once the antibiotic is discontinued. However, patients should be informed that they may experience watery and bloody stools, with or without stomach cramps and fever, even up to 2 months after completing the antibiotic course. If such symptoms occur, patients should be instructed to contact their physician promptly.

Storage and Handling

Capsules are supplied in a package configuration that includes NDC numbers for identification. It is essential to store the capsules at a temperature range of 20°C to 25°C (68°F to 77°F), in accordance with USP Controlled Room Temperature guidelines. Proper storage conditions must be maintained to ensure the integrity and efficacy of the product.

Additional Clinical Information

Periodic assessment of renal, hepatic, and hematopoietic function is recommended for patients undergoing prolonged therapy. Additionally, all patients diagnosed with gonorrhea should undergo a serologic test for syphilis at the time of diagnosis. For those treated with amoxicillin, a follow-up serologic test for syphilis is advised after a period of 3 months.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Amoxicillin as submitted by American Antibiotics, Inc. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)